On Wednesday, May 12, Flexion Therapeutics FLXN will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Net Income, Earnings, And Earnings Per Share
Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.
Earnings And Revenue
Wall Street analysts see Flexion Therapeutics reporting a quarterly loss of $0.52 per share on sales of $24.77 million. Flexion Therapeutics reported a loss of $0.95 when it published results during the same quarter last year. Sales in that period totaled $20.13 million.
Related content: Benzinga's Full Earnings Calendar
Why Analyst Estimates And Earnings Surprises Are Important
Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.
If the company were to report earnings in line when it publishes results Wednesday, earnings would be up 45.26%. Sales would be up 23.07% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q4 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.46 | -0.51 | -0.65 | -0.99 |
| EPS Actual | -0.37 | -0.50 | -0.76 | -0.95 |
| Revenue Estimate | 27.34 M | 23.48 M | 16.34 M | 19.80 M |
| Revenue Actual | 26.31 M | 23.66 M | 15.45 M | 20.13 M |
Stock Performance
Shares of Flexion Therapeutics were trading at $6.99 as of May 10. Over the last 52-week period, shares are down 17.37%. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release.
Do not be surprised to see the stock move on comments made during its conference call. Flexion Therapeutics is scheduled to hold the call at 16:30:00 ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
